# Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

> **NCT05868837** · PHASE3 · RECRUITING · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 40 (estimated)

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **DRUG:** Rituximab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05868837
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-28
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05868837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05868837, "Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05868837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*